信立泰：关于SAL0139获得临床试验批准通知书的公告

Core Points - The company, Xinlitai, has received approval from the National Medical Products Administration for clinical trials of its innovative small molecule drug SAL0139 tablets, aimed at treating hyperlipidemia [2] Group 1 - The approval includes a Clinical Trial Approval Notification, allowing the company to proceed with the clinical trials [2]